Creates grant program in DOH to increase early detection of and intervention for uterine fibroids; appropriates $5 million.
This bill creates a grant program in the Department of Health to support research, public awareness, screening, and intervention efforts aimed at increasing early detection of uterine fibroids. The Commissioner of Health would award grants to organizations for activities such as research on early detection and treatment, public education campaigns, advanced gynecological imaging and screening, patient navigation services, and implementation of evidence-based strategies to improve detection in health care settings. The bill also allows funding for related research on disparities in pain control and management in uterine fibroid surgical treatment, as well as research into Asherman's Syndrome, intrauterine adhesions, and other intrauterine conditions as determined appropriate by the commissioner.
The bill establishes a Uterine Fibroids Prevention Fund in the Department of the Treasury as a nonlapsing, revolving fund to receive state, federal, and private monies and to support the grant program. It appropriates $5 million from the General Fund to the fund for implementation. Grant recipients must track screening rates, early diagnosis rates, reductions in late-stage complications, and patient outcomes, and the Department of Health must report annually to the Governor and Legislature on grant recipients and activities. The bill also directs the Commissioner of Health, in consultation with the Commissioner of Banking and Insurance, to evaluate and recommend policies within one year to ensure coverage for uterine fibroid screening and treatment under state-regulated health plans.
The bill would add a new state grant and funding structure focused on uterine fibroid research, education, screening, and intervention, while creating a dedicated Treasury fund to administer the program. It would also require the Department of Health to develop evidence-based strategies and provider education materials, collect outcome data from grantees, and issue annual reports. In addition, it could influence insurance policy by prompting recommendations for coverage of uterine fibroid screening and treatment under state-regulated health plans, potentially affecting insurers, health care providers, patients, and community-based organizations.
Based on the bill text and available context, the measure appears to be framed positively as a public health and women’s health initiative, with an emphasis on early detection, access to care, and addressing disparities. No committee transcript or recorded vote information is available, so there is no documented opposition or support from hearings or floor action in the provided materials. The overall tone of the bill is preventive and research-oriented, with a clear focus on improving diagnosis and treatment outcomes.
The main potential points of contention are likely to be fiscal and policy-related rather than ideological: the $5 million appropriation, the creation of a new revolving fund, and the possibility of future insurance coverage recommendations could draw scrutiny over cost and implementation. There may also be questions about how grant funds are allocated, what evidence standards will be used to select strategies, and whether the Department of Health should prioritize uterine fibroids over other health conditions. The bill gives priority to organizations partnering with community-based organizations, which may be viewed as beneficial by advocates but could raise questions about grant competitiveness or administrative criteria.